Javier Puente

Como coordinador científico de #SEOM2026, ha sido un privilegio contribuir a un programa que refleja el gran momento de la Oncología Médica: más precisión, innovación y tecnología, pero también más equidad, sostenibilidad y humanidad. 50 años cambiando el significado del cáncer.

Fascinating multi-omic rapid autopsy study on metastatic bladder cancer!
- Polyclonal migration predicts worse clinical outcomes. - Fanconi pathway activation mediates cisplatin resist in aggressive subtypes
- Post-mortem cfDNA liquid biopsies capture tumor heterogeneity

Honored to be a co-author of the KEYNOTE-B15/EV-304 study, now published in @NEJM. Exciting to see practice-changing data that will improve outcomes for patients with muscle-invasive bladder cancer. Congratulations to all investigators! #BladderCancer #MIBC

#ASCO26 CaboNivo remains a strong benchmark in nccRCC, delivering an ORR of 43%, median PFS of 11 m, and OS of 28 m after long-term fu. The real story may be FH-deficient RCC, where ORR reached 88%, reinforcing the need for molecularly driven treatment strategies in rare RCC

#ASCO26 Panitumumab showed remarkable activity in SMARCB1-deficient renal medullary carcinoma, achieving an ORR of 54% with 15% CR in heavily pretreated patients. These data support wild-type EGFR as a promising therapeutic target in one of the most aggressive kidney cancers